COMMUNIQUÉS West-GlobeNewswire

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

26/03/2025 - 21:01

FDA Approval of Emrosi™ ( 40 mg Minocycline Hydrochloride Modified-Release Capsules ) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 [...]

Inventiva reports its 2024 full year results and provides a business update

26/03/2025 - 21:00

Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 [...]

Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité

26/03/2025 - 21:00

Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée d’un produit brut de 116 millions d’euros dans le cadre de la [...]

Heartflow Closes $98 Million Convertible Notes Financing

26/03/2025 - 21:00

Additional Capital to Support Broadening Adoption of a Leading Platform That Transforms Diagnosis and Management of Coronary Artery Disease MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. , the [...]

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

26/03/2025 - 20:12

WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug [...]

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

26/03/2025 - 18:58

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

26/03/2025 - 18:20

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million 1 as of December 31, 2024, ensuring financial visibility until Q1 [...]

OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement

26/03/2025 - 18:20

OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement Revenu total de 83,4 millions d’euros et position de trésorerie 1 de 64,2 millions d’euros au 31 [...]

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

26/03/2025 - 18:00

Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part [...]

Valneva renouvelle son contrat de placement (Sales Agreement) dans le cadre de son programme « At-the-Market (ATM) » existant

26/03/2025 - 18:00

Saint-Herblain (France), 26 mars 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce aujourd’hui qu’elle a déposé auprès de la U.S. [...]

GUERBET : Résultats annuels 2024.

26/03/2025 - 17:45

Résultats annuels 2024 Activité très dynamique Chiffre d’affaires annuel : 841,1 M€, affichant une progression de 9,0% à taux de change constant (TCC) 1 et périmètre comparable 2 Une dynamique soutenue dans la zone [...]

GUERBET : 2024 full-year results.

26/03/2025 - 17:45

2024 full-year results Very strong business momentum Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER) 1 and on a like-for-like basis 2 Strong momentum in the Americas (+20.5% at CER and like- [...]

Trading by management and close relations of management

26/03/2025 - 17:05

Please read the full announcement in PDF Attachment 2025_14_Trading_By_Management

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib

26/03/2025 - 16:50

Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib* 1 BEERSE, BELGIUM, March 26, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & [...]

PrimeBiome Reviews - Is it Worth Buying? Prime Biome Gummies Ingredients, Side Effects, and Investigative Report

26/03/2025 - 16:07

ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- PrimeBioMe is a natural dietary supplement designed to support gut health, improve digestion, and enhance skin appearance. It is made with a blend of plant-based [...]

iTeos présentera les données précliniques d’EOS-215, un anticorps anti-TREM2 supposé meilleur de sa catégorie, et d’un nouvel inhibiteur de PTPN1/2 lors de l’édition 2025 du congrès annuel de l’American Association for Cancer Research

26/03/2025 - 16:02

WATERTOWN, Massachusetts et GOSSELIES, Belgique, 26 mars 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]

OmegaX Health ($OmegaX) Expands to Binance Smart Chain – The Future of AI Healthcare on Blockchain

26/03/2025 - 15:45

ELLWANGEN, Germany, March 26, 2025 (GLOBE NEWSWIRE) -- OmegaX Health ($OmegaX) , a groundbreaking AI-powered healthcare ecosystem, is set to redefine the future of medicine by combining artificial intelligence and [...]

Stryker announces intention to nominate Manny Maceda to board of directors

26/03/2025 - 15:15

Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of [...]

Ivy En Rose Partners with Junior League of San Francisco for Exclusive Community Event on May 8, 2025

26/03/2025 - 15:00

SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- Ivy En Rose , San Francisco’s premier elite MedSpa, is proud to announce an exciting partnership with the Junior League of San Francisco for an exclusive community event [...]